MedTrace Logo

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

NCT05894018 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-05-13

No results posted yet for this study

Summary

To evaluate the effectiveness and safety of radioactive particles in combination with the PARP inhibitor fluzoparib in the treatment of advanced inoperable soft tissue sarcoma.

Conditions

  • Sarcoma,Soft Tissue
  • Brachytherapy
  • Poly(ADP-ribose) Polymerase Inhibitors

Interventions

DRUG

Fluzoparib

150mg, orally, bid

PROCEDURE

Radioactive particle implantation

Radioactive iodine-125 seeds implantation

Sponsors & Collaborators

  • Fujun Zhang

    lead OTHER

Principal Investigators

  • Fujun Zhang, Ph.D,M.D · Sun Yat-sen University

  • Xing Zhang, Ph.D,M.D · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-29
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05894018 on ClinicalTrials.gov